Fundraising Fox
BioMedPartners
Venture capitalBasel · Seed–Late Stage · 26 people tracked
Find your way into BioMedPartners
Each arrow is one introduction. Sign up to fill in the first one.
Ask Kiran Dallenbach to introduce you to Markus Hosang
You →Kiran · together at BioMedPartners →Markus
Ask Jamie Chen to introduce you to Stefan Fäs
You →Jamie · together at BioMedPartners →Stefan
Ask Sam Okafor to introduce you to Michael Wacker
You →Sam · together at Inositec AG →Michael
- Thomas Möller58 people can intro you
- Aristotelis Nastos42 people can intro you
- Dr. Michael Wacker6 people can intro you
Sign up to find every way you can get introduced to BioMedPartners
- Your email: who you already know at BioMedPartners, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the BioMedPartners team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
BiomedVC, founded in 2021 to continue the legacy of BioMedPartners (established 2002), invests in early-stage life science and biotech companies developing innovative therapeutics for high-unmet medical needs. It supports first-time and experienced founders with initial investments at Seed and Series A stages, working as equal partners, leading and co-leading rounds while reserving capital for follow-ons. The firm focuses on continental Europe, particularly the DACH region with an emphasis on Switzerland and Germany, helping transform scientific discoveries from academic labs into venture-backed biotechs. It is currently raising its new fund, BiomedInvest IV, and has already built a significant portfolio of biotech startups.
Source: firm website, verified Sep 27, 2026.
Team · 26 people
from the firm's website & public directories
Founder mafia
3 people who came through BioMedPartners went on to found or lead other companies.
What they invest in
from 9 of 19 portfolio companiesBiotech ×9Healthtech ×8Medical Devices ×5AI & Machine Learning ×2Deep Tech ×2Digital Health ×1Hardware ×1
HQs:Germany×2Switzerland×1France×1Netherlands×1
Investments · 19 tracked
founders shown can be your intro pathBy year:2021 · 12019 · 12 dated
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalFrazier Life SciencesJeito CapitalLongitude CapitalNovo HoldingsOrbiMed+5 more
Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.
BiotechDeep TechHealthtechMedical DevicesLeiden, NL
Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)
Co-investorsBioGeneration VenturesForbionJeito CapitalPictet GroupAsahi Kasei Corporate Venture CapitalSeroba Life Sciences
Antibiotic developer, maker of cefepime/enmetazobactam (EXBLIFEP).
Co-investorsAndera PartnersDelos CapitalEMBL VenturesXeraya CapitalForbion
Clinical-stage biopharmaceutical company developing RNA therapeutics for cardiac disease.
Co-investorscoparionHadean VenturesInkefFund+LSP (Life Sciences Partners)Sunstone Capital
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsBackbone VenturesGimvLightspeed Venture PartnersMission BiocapitalPfizer Venture InvestmentsPfizer Ventures+1 more
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life SciencesForbion+2 more
Immunotherapies for T cell-mediated autoimmune conditions via modulation of coronin 1; spin-off from the University of Basel.
Rajesh Jayachandran, MD PhD(Founder)in
Co-investorsKickfundVenture Kick
Scenic Biotech develops modifier therapy, a genetic medicine approach that targets secondary functions in the genome to neutralize the impact of disease-causing mutations.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Co-investorsBioGeneration VenturesEIR VenturesInkefOxford Science Enterprises
T-CURX is a venture-backed biotechnology company developing autologous CAR-T cell therapies using proprietary non-viral technologies, including in vivo and bedside-manufactured CAR-T approaches based on T cell-targeted LNP delivery of Sleeping Beauty transposon vectors.
BiotechHealthtechWürzburg, DE
Michael Hudecek(Co-founder)Christoph Rader(Co-founder & Member of the Scientific Advisory Board)Ulf Grawunder(Co-founder & CEO)in
Co-investorsHighlight Capitali&i Biotech Fund
TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
Biotech
Co-investorsredalpine
Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases.
BiotechHealthtech
Hugo Fry(Chief Executive Officer)inChristian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)in
Co-investorsEMBL VenturesGimvBoehringer Ingelheim Venture FundEpidarex Capital
TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation.
BiotechHardwareHealthtechMedical DevicesFrance, FR
Ahmed Elmouelhi(President & CEO)inEsther Gerteis(Senior VP Medical & Regulatory Affairs)inMichael Litzenburger(VP R&D)in
Co-investorsEuropean Investment Bank415 CapitalAndera PartnersBayern KapitalKarista
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersAscenta CapitalBayern KapitalcoparionFrazier Life SciencesFund++5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AMAL Therapeutics SADimericon TherapeuticsiDEL Therapeutics GmbHOmnilinX Therapeutics AGPRECIRIX NVSalvina Therapeutics
Exits · 1
1 acquisitionsTubulis GmbHacq. by Gilead Sciences
Portfolio news
latest coverage across their companiesT-CURX · uni-wuerzburg.de · Dec 17, 2025
Azafaros · biospace.com · May 13, 2025
Frequently asked questions
- How many investments has BioMedPartners made?
- BioMedPartners has 19 tracked investments, 1 of which have exited.
- What stage does BioMedPartners invest at?
- BioMedPartners invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What is BioMedPartners's typical check size?
- BioMedPartners typically writes checks of $648K – $6.5M.
- What sectors does BioMedPartners focus on?
- BioMedPartners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is BioMedPartners located?
- BioMedPartners is headquartered in Basel, CH.
- Does BioMedPartners lead rounds?
- Yes, BioMedPartners leads investment rounds.
- Who does BioMedPartners co-invest with?
- BioMedPartners most often shares deals with Andera Partners, Inkef, Jeito Capital, among 47 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.